Searchable abstracts of presentations at key conferences in endocrinology

ea0035p823 | Paediatric endocrinology | ECE2014

Pediatrics cushing disease: a diagnostic challenge

Santos Maria Joana , Martins Sofia , Antunes Ana , Almeida Rui , Marques Olinda

Introduction: Cushing’s disease (CD) is rare in children. It’s most common clinical manifestations are growth retardation, changes in pubertal development and weight gain. The diagnosis, based on clinical suspicion, is often hampered by the non identification of the microadenoma in MRI.Clinical history: A 14-year-old male patient, with short stature, growth arrest after 12 years and weight gain since age of 9. At physical examination, he had mo...

ea0035p944 | Pituitary Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2014

Weight and metabolic profile evolution in patients with treated prolatinomas

Guelho Daniela , Gomes Leonor , Paiva Isabel , Saraiva Joana , Moreno Carolina , Cardoso Luis , Vicente Nuno , Carrilho Francisco

Introduction: The metabolic consequences of hyperprolactinemia and the repercussions of its treatment with dopaminergic agonists are not yet fully understood. This study aims to evaluate the metabolic profile of patients with prolactinomas (prevalence of diabetes mellitus, dyslipidaemia and obesity) and identify the potential variations after treatment with bromocriptine.Methods: Retrospective study of patients followed between 1962 and 2013. Included 17...

ea0070aep486 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Glycemic variability in type 1 diabetes

Santos Tiago , Inácio Isabel , Soares Bruno , Vilaverde Joana , Teixeira Sofia , Cardoso Helena

Introduction: Glycemic variability (GV) is emerging as a measure of glycemic control in type 1 diabetic patients (T1DM) given that it provides an integrated picture of postprandial hyperglycemia and hypoglycemic episodes and is associated with diabetic complications and mortality. However, little is known about the best way to address this problem in clinical practice.Aim: To characterize GV in T1DM patients followed in our center and to identify clinica...

ea0070ep235 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Flash glucose monitoring in type 1 diabetes: Real world data

Borges Duarte Diana , Santos Tiago , Fonseca Liliana , Teixeira Sofia , Vilaverde Joana , Cardoso Maria Helena

Introduction: Clinical trial data demonstrate improved glycemic control in individuals with type 1 diabetes (T1D),especially, reduction of time in hypoglycaemia with flash glucose monitoring (FGM);however real-life conditions can modify this scenario.Aim: To examine real world use and glycemic control following a standardized initiation process of FGM.Methods: Individuals aged 18 years or older with T1D were prospectively recruited...

ea0032p40 | Adrenal cortex | ECE2013

Autoimmune polyglandular syndrome on a cohort of patients with primary adrenocortical insufficiency

Gouveia Sofia , Ribeiro Cristina , Alves Marcia , Saraiva Joana , Moreno Carolina , Guelho Daniela , Carrilho Francisco

Introduction: On average, 40 to 50% of the patients with autoimmune adrenocortical insufficiency will eventually develop an autoimmune polyglandular syndrome (APS). Our aim was to characterize a population with primary adrenocortical insufficiency (AI) and determine the prevalence of other autoimmune disorders that might establish the diagnosis of APS.Materials and methods: We included patients with primary AI under surveillance at our Department. Those ...

ea0032p202 | Cardiovascular Endocrinology &amp; Lipid Metabolism | ECE2013

Dyslipidemia associated with m-TOR inhibitors treatment

Couto Joana , Martins Raquel , Carneiro Filipa , Santos Ana Paula , Torres Isabel

Introduction: Therapeutic approach of patients (pts) with metastatic renal cell carcinoma (mRCC) may include the use of biological agents such as m-TOR inhibitors: temsirolimus (TM) and everolimus (EV). Its use is associated with metabolic dysfunction, especially with everolimus: hyperglycemia (37% TM treated pts vs 72% EV treated pts), hypercholesterolemia (25% TM treated pts vs 81% EV treated pts) and hypertriglyceridemia (30% TM treated pts vs 73% EV treated pts). Discontin...

ea0032p355 | Diabetes | ECE2013

Predictive value of HbA1c and glucose fluctuations in hypoglycemia risk in patients with type 1 diabetes

Guelho Daniela , Barros Luisa , Baptista Carla , Paiva Isabel , Gouveis Sofia , Saraiva Joana , Moreno Carolina , Carrilho Francisco

Introduction: Many patients with diabetes experience high variability in glucose concentrations which is associated with a risk of hypoglycemia. The aim of this was to compare the predictive value of HbA1C, mean interstitial glucose (MIG), and glucose variability (GV) in the risk of hypoglycemia in patients with type 1 diabetes (T1D).Methods: Continuous glucose monitoring, using CGMS system, was performed in 130 T1D patients with diabetes duration of 17....

ea0032p409 | Diabetes | ECE2013

Diabetes and hyperglycemia: relation with clinical outcome in the community acquired pneumonia

Fernandes Vera , Ramalho Julieta , Santos Maria Joana , Oliveira Narciso , Pereira Maria

Background: Community acquired pneumonia (CAP) is a common condition and a major cause of morbidity. Diabetes mellitus (DM) increases the risk and complications of infectious diseases. However, it is necessary to clarify if DM and glycemia at the time of presentation are prognostic factors in patients with CAP.Objectives: To evaluate the relationship between DM/glycemia at the time of presentation and complications, length of stay and mortality in patien...

ea0032p420 | Diabetes | ECE2013

Relationship between metformin treatment and hyperlactacidemia diagnosed at the emergency room

Guelho Daniela , Paiva Isabel , Fonseca Isabel , Gouveia Sofia , Saraiva Joana , Moreno Carolina , Carvalheiro Manuela , Carrilho Francisco

Introduction: Renal function and glucose lowering therapy, particularly metformin, influence serum lactate concentration in patients with type 2 diabetes (T2D). However, seems to be an acute precipitating event that triggers hyperlactacidemia and metabolic acidosis. This study aims to assess prevalence of hyperlactacidemia in T2D patients who presented at emergency room (ER), calculate relative risk of hyperlactacidemia in diabetics under metformin, identify predictive factors...

ea0032p1027 | Thyroid (non-cancer) | ECE2013

Thyroid diffuse lipomatosis: a rare and benign disease

Lau Eva , Freitas Paula , Goncalves Frederica , Pardal Joana , Eloy Catarina , Matos-Lima Luis , Carvalho Davide

Introduction: Diffuse lipomatosis of the thyroid is a very rare disease, characterized by extensive infiltration of thyroid parenchyma by mature adipose tissue. It is not accompanied by accumulation of amyloid fibrils.Clinical report: Male, 47 years old, followed in Endocrinology by hypothyroidism, since 13 years old, medicated with levothyroxine, with unremarkable growth and pshicomotor development. In 2002, thyroid echography showed a solid and heterog...